

Psychotropic Agents for Children Age 0 to 5

Please provide the information below. Please print your answer, attach supporting documentation, sign, date, and return to our office as soon as possible to expedite this request. FAX responses to: (844) 259-1689. Phone: (833) 685-2103.

DATE OF REQUEST:									
MEMBER INFORMATION									
Nar	ne:				DOB:	Molina ID:			
PRESCRIBING PROVIDER INFORMATION									
Name:				NPI:		Specialty:			
Contact person for request:				Fax (required):		Phone:			
REQUESTED DRUG									
Drug Name: Strength:			Strength:	Dosage:		Duration:			
 Medication is an anticonvulsant used to treat a seizure disorder – No further documentation required. The request is for initiation of therapy (recipient has not started therapy). The request is for continuation of therapy. The recipient is currently stabilized on the requested medication. Recipient was recently discharged (within 30 days) from an institutional facility on the requested medication; if yes, document: the name of the facility: 									
TREATMENT DIAGNOSIS									
Diagnosis or Diagnosis Code (list ONE only): Peer-reviewed literature/citation has been included if the requested agent is not FDA-approved for the specific diagnosis. PSYCHOTROPIC AGENTS CURRENTLY PRESCRIBED									
Dru			ment Diagnosis		Target Symptom	and/or side-effect:			
PR		TION CRITERIA	(Per MSM Cha	apter 1200)					
For Tar Tar		uests treating the Psychosis Impulsivity Sedation Dystonia	e same diagnos Dep Irrita Res Trer	sis; docum ression ability tlessness	eymptom and/or diagnosis ent the specific target s Anxiety Aggression Other Dyskinesi	ymptom or side-effect: □ Inattentiveness □ Oppositional			
	B. When medication used to augment the effect of another psychotropic for the same diagnosis, the recipient's medical								
C.	 record must clearly document the purpose of the poly-pharmacy. Purpose:								

ADDITIONAL INFORMATION								
Please document any additional information for consideration (intra-class polypharmacy or previous agents tried and failed):								
PREFERRED DRUG LIST CRITERIA - <i>Required for requested agents that are non-preferred.</i> A copy of the Preferred Drug List (PDL) can be found at: medicaid.nv.gov/providers/rx/pdl.aspx								
	The recipient has allergy(ies) to <u>ALL</u> preferred medications; document each reaction below.							
	The recipient has a contraindication(s) to <u>ALL</u> preferred medications; document each contraindication below.							
	The recipient has a drug-to-drug interaction(s) with <u>ALL</u> preferred medications; document each interaction below.							
	The recipient has had therapeutic failure with at least two preferred psychotropics or, if the request is for an antipsychotic, the recipient has had therapeutic failure with at least one preferred antipsychotic; document each agent below.							
	The requested agent is being used for an indication which is unique to a non-preferred agent and is supported by peer-							
	reviewed literature or an FDA-approved							
Document each agent from the above section or any other agents previously tried and failed.								
	Drug:	Reason:	Date(s) of Trial:					
_								
COVERAGE AND LIMITATIONS (Per MSM Chapter 1200)								
For All Requests:								
	 When possible, the requested agent is prescribed by or in consultation with a child psychiatrist. Recipient has a comprehensive treatment plan that addresses education, behavioral management, living home 							
	environment and psychotherapy.							
	 The recipient will be monitored by the prescriber at least <u>monthly (recipient is unstable)</u>. The recipient will be monitored by the prescriber at least <u>every three months (recipient is stable)</u>. 							
PROVIDER CERTIFICATION – Prescriber's signature and date required.								
		ated and necessary and meets the guidelines t	for use as outlined by Nevada					

Medicaid.
Prescriber's Signature:

Date:

This authorization request is not a guarantee of payment. Payment is contingent upon eligibility, available benefits, contractual terms, limitations, exclusions, coordination of benefits and other terms and conditions set forth by the benefit program. The information on this form and on accompanying attachments is privileged and confidential and is only for the use of the individual or entities named on this form. If the reader of this form is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, the reader is hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If this communication is received in error, the reader shall notify sender immediately and destroy all information received.